# ViGeneron jobs and careers

> 0 open roles at ViGeneron as of October 23, 2026. Source: https://www.thejobsmap.com/company/vigeneron

ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vectorplatform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Headquarters | Starnberg, Germany |
| Founded | 2017 |
| Employees | 1 to 10 |
| Industries | Biotechnology, Health Care, Therapeutics |
| Website | https://vigeneron.com |

## Leadership

- Caroline Man Xu, Co-Founder & CEO
- Elvir Becirovic, Chief Technology Advisor
- Stylianos Michalakis, Scientific Co-Founder & Chief Scientific Advisor
- Martin Biel, Scientific Co-Founder & Chairman of Scientific Advisory Board
- Gang Pei, Scientific Advisor
- Siegfried Priglinger, Scientific Advisor

## Common questions

### Is ViGeneron hiring right now?

ViGeneron has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on ViGeneron's careers site.

### Where is ViGeneron headquartered?

ViGeneron is headquartered in Starnberg, Germany and was founded in 2017.

### Who leads ViGeneron?

Caroline Man Xu, Co-Founder & CEO, is at the top of ViGeneron's org chart.

### How do I apply for a job at ViGeneron?

Pick a role on ViGeneron's TheJobsMap page and select Apply. Every listing links to the original posting on ViGeneron's own careers site, so you apply directly with the employer.